The invention relates to pharmaceutical industry and discloses a method of obtaining a new pharmacologically active liposomal agent containing substances that exhibit specific pharmacological activity on peripheral vessels and cavernous bodies of a mammal. More particularly, the invention relates to a method of obtaining a pharmacologically active liposomal cytochrome c containing nitric oxide. The new liposomal agent acts as a donor of the key biologically active substancenitric oxide (NO).

A method of obtaining a pharmacologically active liposomal cytochrome c and nitric oxide complex comprises the treatment of the liposomal cytochrome c emulsion with gaseous nitric oxide (NO) until liposomal cytochrome c is completely reconstituted and the addition of an S-nitroso compound to the liposomal cytochrome c emulsion.

Disclosed herein are methods and compositions to treat solid tumors. In one embodiment, the method of treating a solid tumor in a patient includes administering at the tumor site a therapeutically effective amount of cytochrome P450 producing cells encapsulated in a capsule and administering a prodrug which is activated by cytochrome P450, wherein the prodrug is administered at least three or more cycles, and wherein each cycle comprises three consecutive daily administration.

The present disclosure provides a recombinant adeno-associated vector comprising a codon-optimized sequence encoding CYP4V2 linked to selected gene expression regulatory sequences and its use in treating Bietti Crystalline Dystrophy (BCD).

This invention relates to pharmaceutics and a method of producing of liposomal composition containing cytochrome c and the pharmacologically active liposomal composition obtained by this method, which can be used as a means of polyfunctional pharmacotherapy, especially for ophthalmology, hematology and cardiology.

A method of producing of liposomal composition containing cytochrome c, the method includes preparing mixture of solutions of lipids in an organic solvents, drying in vacuum the mixture and emulsifying it in aqueous medium containing cytochrome c, adding of cryoprotectant, homogenization of the emulsion, filtration and freeze-drying, and according to the invention the lipids are egg or soybean phosphatidylcholine with one or two of lipids from the group consisting of dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diphosphatidylglycerol, phosphatidylglycerol, phosphatidylinositol or dioleoyloxypropy trimethylammonium, whereas the ratio of phosphatidylcholine:to other lipids is 0.3-2.0:1, thereby to prepare the mixture of solutions of lipids, phosphatidylcholine is dissolved in ethyl alcohol, and other lipidsin chloroform and a volume ratio in a mixture of solutions of ethyl alcohol:chloroform is 1:1.5-2.5, emulsification is performed at a weight ratio of cytochrome c to lipids of 1:11.4-18.5 adding a cryoprotectant solution to the aqueous medium, and the cryoprotectant is selected from lactose, trehalose, sucrose oligosaccharides, wherein the said solution contains 60-80% of total cryoprotectant, and homogenization with step-by-step increasing pressure from 300 to 800 atm, after its completion a solution of selected cryoprotectant is added to emulsion, wherein solution contains 40-20% of total cryoprotectant, and the weight ratio of lipids mixture to cryoprotectant is 1:5.5-7.2.

It is claimed a liposomal composition containing cytochrome c, lipids and cryoprotectant, which is performed according to the method above, and the composition includes egg or soybean phosphatidylcholine in mixture with one or two of lipids from the group consisting of dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diphosphatidylglycerol, phosphatidylglycerol, phosphatidylinositol or dioleoyloxypropy trimethylammonium, and cryoprotectant is selected from lactose, trehalose, sucrose oligosaccharides, wherein the weight ratio of cytochrome c:phosphatidylcholine:other lipids:cryoprotectant is 1:2.9-8.6:4.3-15.7:78.6-102.8 and percentage content ratio is (0.81-1.06)%:(3.03-8.26)%:(4.13-9.88)%:(78.67-83.30)% respectively.

It is disclosed herein that microperoxidases are capable of binding carbon monoxide (CO) with high affinity and displacing CO from hemoglobin, thereby acting as CO scavengers. The present disclosure provides methods of treating carboxyhemoglobinemia (or CO poisoning) in a subject by administering a therapeutically amount of an isolated or recombinant microperoxidase. Methods of removing CO from hemoglobin in blood or tissue by administering a therapeutically amount of an isolated or recombinant microperoxidase are also described. Methods of determining the effectiveness of a microperoxidase for removing CO from hemoglobin are further described.

The present invention relates to disintegratable core/shell silica particles encapsulating a bioactive macromolecule or bioactive macromolecule cluster in an active conformation, a method for producing the same, and uses thereof.

The present disclosure provides a recombinant adeno-associated vector comprising a codon-optimized sequence encoding CYP4V2 linked to selected gene expression regulatory sequences and its use in treating Bietti Crystalline Dystrophy (BCD).

Described herein are methods for treating an autoimmune or inflammatory disease in a patient, comprising administering a composition comprising: a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2.sub.353-367, PDC-E2.sub.72-86, and PDC-E2.sub.422-436 for DRB3*0202; PDC-E2.sub.353-367, PDC-E2.sub.80-94, and PDC-E2.sub.535-549 for DRB5*0101; PDC-E2.sub.629-648, PDC-E2.sub.122-135, and PDC-E2.sub.249-263 for DRB4*0101; and PDC-E2.sub.249-263 for DRB1*0801; and b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers; wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.